Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating brain glioma

A brain glioma and composition technology, applied in the field of medicine, can solve the problems of high toxic and side effects, high price of temozolomide, and thrombocytopenia, and achieve the effects of low price, significant curative effect, and low toxic and side effects

Inactive Publication Date: 2014-07-23
朱启顺 +1
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The advantage of temozolomide for the treatment of glioma is that the drug can penetrate the blood-brain barrier and has a significant curative effect, but the biggest disadvantage of the drug alone is that it has large toxic and side effects.
Its toxic and side effects are mainly neutropenia, thrombocytopenia, loss of appetite, headache, constipation, hair loss, fatigue, diarrhea and blurred vision, so it is difficult for tumor patients to tolerate, and it is easy to develop drug resistance and cannot be used for a long time
In addition, the price of temozolomide is high, and the financial burden on patients is heavy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating brain glioma
  • Pharmaceutical composition for treating brain glioma
  • Pharmaceutical composition for treating brain glioma

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0027] Example 1: Determination of the inhibitory effect of artemether and temozolomide alone and in combination on C6 glioma cells.

[0028] Experimental reagents: RPMI1640 medium was purchased from GIBCO Company of the United States; fetal bovine serum was purchased from GIBCO Company of the United States, thiazolyl blue (MTT) was purchased from SIGMA Company of the United States, and DMSO was purchased from SIGMA Company of the United States.

[0029] Main instruments: carbon dioxide incubator (Forma, USA); microplate reader (Bio-Rad, USA); aseptic operating table (Forma, USA).

[0030] Cell lines and cell culture: SD rat glioma cell line C6 was cultured with RPMI1640 cells containing 10% fetal bovine serum at 37°C, 5% CO 2 Routine cultivation in a constant temperature incubator.

[0031] Drug: artemether (Kunming Pharmaceutical Group Co., Ltd., 50 mg).

[0032] Temozolomide (Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., 50mg).

[0033] Test method: Tetramethylazozolium s...

example 2

[0043] Example 2: Effects of artemether and temozolomide alone and in combination on the morphology of C6 cells

[0044] Main reagents: RPMI1640 medium was purchased from GIBCO Company of the United States; fetal bovine serum was purchased from GIBCO Company of the United States, and 0.25% trypsin was purchased from GIBCO Company of the United States.

[0045] Main instruments: carbon dioxide incubator (Forma, USA); inverted microscope (Leica, Germany); aseptic operating table (Forma, USA).

[0046] Cell lines and cell culture: Rat glioma cell line C6 was cultured with RPMI1640 cells containing 10% fetal bovine serum in a constant temperature incubator at 37°C and 5% CO2.

[0047] Drug: artemether (Kunming Pharmaceutical Group Co., Ltd., 50 mg).

[0048] Temozolomide (Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., 50mg).

[0049] experimental method:

[0050] Take 1×10 C6 cells in the logarithmic growth phase 6 / ml inoculated in a 6-well plate. The experiment consisted of a ...

example 3

[0053] Example 3: Study on the synergistic inhibitory effect of artemether and temozolomide on rat C6 orthotopic glioma:

[0054] Materials: SD rat C6 glioma cell line was provided by Kunming Institute of Zoology, Chinese Academy of Sciences;

[0055] Experimental animals: adult SD rats, weighing 200-250g, 48 males (provided by Kunming Medical University, approval number: SCXK Dian P0005-0008);

[0056] Reagents: RPMI1640 medium was purchased from GIBCO, USA; fetal bovine serum was purchased from GIBCO, USA, and 0.25% trypsin was purchased from GIBCO, USA.

[0057] Instruments: carbon dioxide incubator (Forma, USA); inverted microscope (Leica, Germany); aseptic operating table (Forma, USA); stereotaxic brain (Shenzhen Ruiwode Life Technology Co., Ltd.).

[0058] Drug: artemether (Kunming Pharmaceutical Group Co., Ltd., 50 mg).

[0059] Temozolomide (Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., 50mg).

[0060] experimental method:

[0061] C6 cells were inoculated at 50cm a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for treating brain glioma and belongs to the field of medicines. The pharmaceutical composition which takes artemether and temozolomide as active components comprises the active components in parts by weight: 40-70 parts of artemether and 0.5-4.0 parts of temozolomide, further preferably 65-67 parts of artemether and 0.5-2.0 parts of temozolomide. The pharmaceutical composition provided by the invention has a remarkable inhibiting effect to the C6 cell line of brain glioma of a SD rat cultured in vitro. The effect of using artemether and temozolomide in a combined or independent manner is in time and concentration dependency, and the artemether and temozolomide which are combined in use are in synergic relationship. When the artemether and temozolomide which are combined in use, IC50 value is lower than that when the artemether and temozolomide are independently used. Animal experiments sufficiently prove that when the artemether and temozolomide are combined in use, a good antitumor effect is achieved, and is stronger than that when the artemether and temozolomide are independently used; pathological section results show that when the artemether and temozolomide are combined in use, the quantity of microvessels of brain glioma is remarkably reduced, and the anti-angiogenic effect is stronger than that when the artemether and temozolomide are independently used. The pharmaceutical composition has the advantages of low price, remarkable curative effect and low toxic and side effect.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a pharmaceutical composition for treating glioma. Background technique [0002] Gliomas account for about 46% of intracranial tumors. Malignant glioma is the second cause of death in tumor patients under the age of 34, and the third cause of death in patients aged 35 to 54. The benign glioma grows slowly and has a long course of disease, with an average time of two years from the onset of symptoms to seeing a doctor; the malignant tumor grows fast and has a short course of disease, and most of them are within 3 months from the onset of symptoms to seeing a doctor, 70% to 80% % within half a year. Chemotherapy drugs used in routine cancer treatment are highly toxic and have a high recurrence rate, and most of them cannot penetrate the blood-brain barrier. It is of great value to find low-toxicity, high-efficiency, cheap drugs that can penetrate the blood-brain barrier and can be used to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4188A61P35/00A61K31/357
Inventor 朱啟顺伍治平高诚伟吴永贵康红梅陈艳
Owner 朱启顺
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com